Apolipoproteins: New players in cancers

Yingcheng He; Yingcheng He; Jianrui Chen; Jianrui Chen; Yanbing Ma; Yanbing Ma; Hongping Chen; Hongping Chen

doi:10.3389/fphar.2022.1051280

Frontiers in Pharmacology (Nov 2022)

Apolipoproteins: New players in cancers

Yingcheng He,
Yingcheng He,
Jianrui Chen,
Jianrui Chen,
Yanbing Ma,
Yanbing Ma,
Hongping Chen,
Hongping Chen

Affiliations

Yingcheng He: Department of Histology and Embryology, Medical College of Nanchang University, Nanchang, Jiangxi, China
Yingcheng He: Medical Department, Queen Mary School, Nanchang University, Nanchang, Jiangxi, China
Jianrui Chen: Department of Histology and Embryology, Medical College of Nanchang University, Nanchang, Jiangxi, China
Jianrui Chen: Medical Department, Queen Mary School, Nanchang University, Nanchang, Jiangxi, China
Yanbing Ma: Department of Histology and Embryology, Medical College of Nanchang University, Nanchang, Jiangxi, China
Yanbing Ma: Medical Department, Queen Mary School, Nanchang University, Nanchang, Jiangxi, China
Hongping Chen: Department of Histology and Embryology, Medical College of Nanchang University, Nanchang, Jiangxi, China
Hongping Chen: Jiangxi Key Laboratory of Experimental Animals, Nanchang University, Nanchang, Jiangxi, China

DOI: https://doi.org/10.3389/fphar.2022.1051280
Journal volume & issue: Vol. 13

Abstract

Read online

Apolipoproteins (APOs), the primary protein moiety of lipoproteins, are known for their crucial role in lipid traffic and metabolism. Despite extensive exploration of APOs in cardiovascular diseases, their roles in cancers did not attract enough attention. Recently, research focusing on the roles of APOs in cancers has flourished. Multiple studies demonstrate the interaction of APOs with classical pathways of tumorigenesis. Besides, the dysregulation of APOs may indicate cancer occurrence and progression, thus serving as potential biomarkers for cancer patients. Herein, we summarize the mechanisms of APOs involved in the development of various cancers, their applications as cancer biomarkers and their genetic polymorphism associated with cancer risk. Additionally, we also discuss the potential anti-cancer therapies by virtue of APOs. The comprehensive review of APOs in cancers may advance the understanding of the roles of APOs in cancers and their potential mechanisms. We hope that it will provide novel clues and new therapeutic strategies for cancers.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords